Sava Raises $36M for Glucose Microsensor
Sava Technologies has raised $36M to advance a wearable microsensor platform for glucose monitoring.
Continuous glucose monitoring is a large and established market, but current sensors are still relatively invasive and dominated by a small number of incumbents.
What happened
Sava Technologies raised a $36 million Series B to advance its wearable microsensor platform.
The company's technology measures molecules beneath the skin and is initially focused on glucose monitoring.
A major diabetes-care company is also joining as an investor and commercial partner for Europe.
Why it matters
A smaller and potentially less invasive sensing platform could improve user comfort and broaden adoption.
The same underlying sensor architecture may also have applications beyond glucose if it can reliably measure additional biomarkers.
The bigger picture
Wearable health technology is moving from simple activity tracking toward continuous biochemical sensing.
The companies that succeed will need to combine reliable hardware, clinical validation, regulatory approval and strong distribution.
Sava's financing and commercial partnership give it a clearer route toward that market.